Synonyms: Buccolam® | Dormicum® | Nayzilam® | USL261 (nasal spray formulation) [1] | Versed®
midazolam is an approved drug (FDA (2000), EMA (2011))
Compound class:
Synthetic organic
Comment: Midazolam is a benzodiazepine class sedative drug.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Bancke LL, Dworak HA, Rodvold KA, Halvorsen MB, Gidal BE. (2015)
Pharmacokinetics, pharmacodynamics, and safety of USL261, a midazolam formulation optimized for intranasal delivery, in a randomized study with healthy volunteers. Epilepsia, 56 (11): 1723-31. [PMID:26332539] |
2. Detyniecki K, Van Ess PJ, Sequeira DJ, Wheless JW, Meng TC, Pullman WE. (2019)
Safety and efficacy of midazolam nasal spray in the outpatient treatment of patients with seizure clusters-a randomized, double-blind, placebo-controlled trial. Epilepsia, 60 (9): 1797-1808. [PMID:31140596] |
3. Drummond AH, Hughes PJ, Ruiz-Larrea F, Joels LA. (1989)
Use of receptor antagonist in elucidating the mechanism of action of TRH in GH3 cells. Ann N Y Acad Sci, 553: 197-204. [PMID:2566295] |
4. Waugh DJ, Gaivin RJ, Damron DS, Murray PA, Perez DM. (1999)
Binding, partial agonism, and potentiation of alpha(1)-adrenergic receptor function by benzodiazepines: A potential site of allosteric modulation. J Pharmacol Exp Ther, 291 (3): 1164-71. [PMID:10565838] |
5. Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, Hamman MA, Hall SD, Wrighton SA. (2002)
Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos, 30 (8): 883-91. [PMID:12124305] |